|
Peptide inhibitors of the Keap1–Nrf2 protein–protein interaction
|
journal
|
January 2012 |
|
Getting in Shape: Controlling Peptide Bioactivity and Bioavailability Using Conformational Constraints
|
journal
|
November 2012 |
|
Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors
|
journal
|
February 2016 |
|
Improving on Nature: Making a Cyclic Heptapeptide Orally Bioavailable
|
journal
|
September 2014 |
|
Role of the Keap1/Nrf2 pathway in neurodegenerative diseases: Nrf2 and neurodegenerative diseases
|
journal
|
February 2015 |
|
Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads
|
journal
|
May 2010 |
|
Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges
|
journal
|
February 2019 |
|
Discovery of direct inhibitors of Keap1–Nrf2 protein–protein interaction as potential therapeutic and preventive agents
|
journal
|
July 2015 |
|
Binding Efficiency of Protein–Protein Complexes
|
journal
|
November 2012 |
|
Enzymatic Transition States and Drug Design
|
journal
|
October 2018 |
|
A theoretical foundation for the PLS algorithm
|
journal
|
January 1987 |
|
Orally Absorbed Cyclic Peptides
|
journal
|
May 2017 |
|
Crystal-contact engineering to obtain a crystal form of the Kelch domain of human Keap1 suitable for ligand-soaking experiments
|
journal
|
May 2013 |
|
Critical Effect of Peptide Cyclization on the Potency of Peptide Inhibitors against Dengue Virus NS2B-NS3 Protease
|
journal
|
July 2012 |
|
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
|
journal
|
January 2019 |
|
Improved WATERGATE Pulse Sequences for Solvent Suppression in NMR Spectroscopy
|
journal
|
May 1998 |
|
Keap1 Recruits Neh2 through Binding to ETGE and DLG Motifs: Characterization of the Two-Site Molecular Recognition Model
|
journal
|
April 2006 |
|
Binding Affinity Prediction for Protein–Ligand Complexes Based on β Contacts and B Factor
|
journal
|
November 2013 |
|
Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?
|
journal
|
September 2013 |
|
PLS-regression: a basic tool of chemometrics
|
journal
|
October 2001 |
|
Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions
|
journal
|
November 1992 |
|
Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency
|
journal
|
January 2018 |
|
A Comparative Assessment Study of Known Small-Molecule Keap1−Nrf2 Protein–Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity
|
journal
|
August 2019 |
|
The exploration of macrocycles for drug discovery — an underexploited structural class
|
journal
|
July 2008 |
|
Perfluoroarene-based peptide macrocycles that inhibit the Nrf2/Keap1 interaction
|
journal
|
September 2018 |
|
Going Out on a Limb: Delineating The Effects of β-Branching, N -Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues
|
journal
|
September 2015 |
|
Rapid Flow-Based Peptide Synthesis
|
journal
|
March 2014 |
|
MOrPH-PhD: An Integrated Phage Display Platform for the Discovery of Functional Genetically Encoded Peptide Macrocycles
|
journal
|
February 2020 |
|
Binding thermodynamics and kinetics guided optimization of potent Keap1–Nrf2 peptide inhibitors
|
journal
|
January 2015 |
|
Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2
|
journal
|
July 2005 |
|
Comprehensive Experimental and Computational Analysis of Binding Energy Hot Spots at the NF-κB Essential Modulator/IKKβ Protein–Protein Interface
|
journal
|
April 2013 |
|
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
|
journal
|
October 2015 |
|
Macrocycles in new drug discovery
|
journal
|
July 2012 |
|
Progress towards the broad use of non-peptide synthetic macrocycles in drug discovery
|
journal
|
January 2017 |
|
The Anti-Inflammatory and Anti-Oxidant Mechanisms of the Keap1/Nrf2/ARE Signaling Pathway in Chronic Diseases
|
journal
|
January 2019 |
|
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
|
journal
|
November 1995 |
|
Crystal Structures of Protein-Bound Cyclic Peptides
|
journal
|
May 2019 |
|
Macrocycles: lessons from the distant past, recent developments, and future directions
|
journal
|
January 2015 |
|
Discovery of Kinase Spectrum Selective Macrocycle (16 E )-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer
|
journal
|
December 2011 |
|
Interaction Energetics and Druggability of the Protein–Protein Interaction between Kelch-like ECH-Associated Protein 1 (KEAP1) and Nuclear Factor Erythroid 2 Like 2 (Nrf2)
|
journal
|
December 2019 |
|
Industrial PLS model variable selection using moving window variable importance in projection
|
journal
|
July 2014 |
|
Modified Peptide Inhibitors of the Keap1–Nrf2 Protein–Protein Interaction Incorporating Unnatural Amino Acids
|
journal
|
July 2018 |
|
LigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug Discovery
|
journal
|
October 2011 |
|
Design, Synthesis, and Anaplastic Lymphoma Kinase (ALK) Inhibitory Activity for a Novel Series of 2,4,8,22-Tetraazatetracyclo[14.3.1.1 3,7 .1 9,13 ]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene Macrocycles
|
journal
|
December 2011 |
|
Tools and rules for macrocycles
|
journal
|
July 2014 |
|
Keap1 Is a Redox-Regulated Substrate Adaptor Protein for a Cul3-Dependent Ubiquitin Ligase Complex
|
journal
|
December 2004 |
|
Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
|
journal
|
December 2013 |
|
New Frontiers in Druggability
|
journal
|
August 2015 |
|
Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products
|
journal
|
May 2015 |
|
Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein–Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery
|
journal
|
April 2016 |
|
How proteins bind macrocycles
|
journal
|
July 2014 |
|
Molecular Properties That Influence the Oral Bioavailability of Drug Candidates
|
journal
|
June 2002 |
|
Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling
|
journal
|
August 2006 |
|
Small molecules inhibiting Keap1–Nrf2 protein–protein interactions: a novel approach to activate Nrf2 function
|
journal
|
January 2017 |
|
Macrocyclic Inhibitors of β-Secretase: Functional Activity in an Animal Model
|
journal
|
October 2006 |
|
Kinetic Analyses of Keap1-Nrf2 Interaction and Determination of the Minimal Nrf2 Peptide Sequence Required for Keap1 Binding Using Surface Plasmon Resonance: Kinetic Analyses of Keap1-Nrf2 Peptide Interactions
|
journal
|
October 2011 |
|
Structure-Based Design of High-Affinity Macrocyclic Peptidomimetics to Block the Menin-Mixed Lineage Leukemia 1 (MLL1) Protein–Protein Interaction
|
journal
|
January 2013 |
|
Different Electrostatic Potentials Define ETGE and DLG Motifs as Hinge and Latch in Oxidative Stress Response
|
journal
|
November 2007 |
|
Principal component analysis
|
journal
|
August 1987 |
|
Passive Membrane Permeability in Cyclic Peptomer Scaffolds Is Robust to Extensive Variation in Side Chain Functionality and Backbone Geometry
|
journal
|
October 2016 |
|
Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug Discovery
|
journal
|
April 2011 |